Cited 15 times in
Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.